In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. FDA Seizes 33 Products From India's Sun-owned Caraco Detroit Site

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - U.S. FDA toughened its stand on generic drug maker Caraco, ordering it to immediately stop distributing its drugs until the agency had assurance that the firm had complied with its good manufacturing practices

You may also be interested in...



Caraco Feels The Sting Of FDA's Accelerated Response To GMP Violations

FDA's fast action to seize drug products and ingredients at three Michigan facilities owned by Caraco Pharmaceutical Laboratories could reflect pressure from Reps. John Dingell and Bart Stupak to tighten controls on generic manufacturers

Caraco Feels The Sting Of FDA's Accelerated Response To GMP Violations

FDA's fast action to seize drug products and ingredients at three Michigan facilities owned by Caraco Pharmaceutical Laboratories could reflect pressure from Reps. John Dingell and Bart Stupak to tighten controls on generic manufacturers

Sun Feels The Heat As FDA Seizes Caraco Drugs; To Sign Consent Decree And Reset Guidance

MUMBAI - Days after U.S. FDA ordered seizure of 33 products from Caraco's Detroit-based manufacturing unit, its Indian parent Sun Pharma told investors that it will withdraw its earnings guidance and revise at a later date. Sun Pharma had set a guidance of 13-15 percent growth in 2009-10

Related Content

UsernamePublicRestriction

Register

SC072028

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel